An updated evidence-based practice guideline published in Headache outlines when to initiate pharmacologic migraine prevention in adults and how to select, assess, and discontinue treatment.
Clinical and pharmacokinetic evidence supported approval of zilganersen across pediatric and adult age groups, providing the first therapy designed to reduce production of the abnormal GFAP protein...
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
In a resting-state fMRI study of adults with episodic migraine, chronic migraine, and healthy controls, migraine was associated with reduced brain entropy, with partial entropy restoration during attacks.
...
Featured faculty at The Revolution & Paradigm Shift in Treatment of Migraine, scheduled for July 16-17, 2026, will highlight evolving approaches to migraine diagnosis, prevention, disease burden, and...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, addressed migraine-related diagnosis, treatment, red flags, and care considerations across...
